Mesoblast advancing towards Phase III trials
13 July, 2010 by Staff WritersAustralian regenerative medicine company Mesoblast has formally begun perusing FDA approval for Phase III clinical trials of its bone marrow transplant allogeneic following positive results from a trial at the University of Texas Md Anderson Cancer Centre.
Market Report: Shares rise on strong jobs figures and a resurgent Wall Street
09 July, 2010 by David BinningThe Australian stock market managed its strongest close in a month today spurred by better-than-expected Australian employment data as well as improved confidence in the U.S economy following three days of consecutive gains on Wall Street.
Avexa appoints new chairman
09 July, 2010 by David BinningHIV drug company Avexa has appointed industry veteran Joe Baini as its new chairman after shareholders voted on Tuesday to remove his predecessor Nathan Drona and virtually the company’s entire board.
Clinuvel signs first manufacturing deal for Scenesse
08 July, 2010 by David BinningMelbourne biotech Clinuvel (ASX:CUV) has struck the first commercial manufacturing deal for its UV-protection drug Scenesse.
AusBiotech positive about working with Julia Gillard
07 July, 2010 by David BinningPeak industry body AusBiotech said today that it was confident of working with new prime minister Julia Gillard to develop a more effective legislative framework for the Australian biotechnology industry.
AtCor adds to run of sales since March
07 July, 2010 by David BinningAtCor Medical announced today that it has signed a US$1.77 million contract for the supply of its SphygmoCor blood pressure measurement system to a U.S customer.
Avexa axes board
06 July, 2010 by David BinningShareholders in Avexa today voted resoundingly in favour of ousting existing chairman and director Nathan Drona along with the company’s entire board.
Patrys granted U.S patent for lead human anti-body product
06 July, 2010 by David BinningPatrys announced today that it has received a U.S patent for its lead product PATPM1, a promising new human antibody shown to be effective in the treatment of solid tumors and metastases across a number of indicators including pancreatic, lung, breast, colon and gastric cancers.
Market Report: fears of double dip U.S recession continue to haunt
02 July, 2010 by David BinningAustralian shares staged a small comeback on Friday ending eight days of consecutive losses incured as investors eyed the looming spectre of a double-dip recession in the U.S, while data out of China showed that measures aimed at slowing its economy were working.
Clinuvel awarded U.S patent for use of Scenesse in UV protection
02 July, 2010 by Staff WritersMelbourne-based Clinuvel has received a U.S patent acknowledging the role of so-called melanocortin drugs in providing UV protection for fair skinned people who have a genetic variation in the melanocortin-1 receptor (MC1R).
Abbott rumoured to be selling flu vaccine business
02 July, 2010 by David BinningAbbott Laboratories is believed to be considering the sale of its flu business, gained earlier in the year through its acquisition of Belgium’s Solvay Pharmaceuticals.
Novartis to outperform wider pharma industry
01 July, 2010 by David BinningSwiss-based Novartis is expected to be the world’s best performing pharmaceutical company over the next five years, bolstered by its vaccine and generics businesses.
Roundtable: from innovation to commercialisation - Part II: the valley of death
29 June, 2010 by Tim DeanIn this section of the roundtable the panellists discussed the so-called 'valley of death' between a promising discovery and having a product that the industry will actually put money behind.
Amgen ready to go shopping
28 June, 2010 by David BinningGlobal biotech company Amgen has acknowledged that proposed changes to the R&D tax credit arrangements would increase the appeal of the Australian biotech industry as the company prepares to embark on a global spending spree.
Roundtable: from innovation to commercialisation - Part I: research and business
28 June, 2010 by Tim DeanIt's the perennial question: how do we effectively translate cutting edge research into successful products in the market? Australian Life Scientist brought together a panel of industry luminaries to discuss the challenges of commercialisation in Australia.
